APOPTOTIC EFFECT IN COMBINATION OF CYCLOSPORIN A AND TAXOL ON ORAL SQUAMOUS CELL CARCINOMA CELL LINE THROUGH THE PI-3 KINASE/AKT1 PATHWAY

구강 편평세포암종 세포주에서 Cyclosporin A와 Taxol 투여시 PI-3 kinase/Akt1 Pathway에 의한 세포사멸 병용효과

  • Kim, Kyu-Young (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University) ;
  • Lee, Jae-Hoon (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University)
  • 김규영 (단국대학교 치과대학 구강악안면외과학교실) ;
  • 이재훈 (단국대학교 치과대학 구강악안면외과학교실)
  • Published : 2007.10.31

Abstract

Oral cancer take up 2-6% of all carcinomas and squamous cell carcinoma, which is the most common type in oral cancer, has a poor prognosis due to its high metastasis and recurrence rates. In treating oral cancer, chemotherapy to the primary, metastasized and recurrent lesion is a very important and useful treatment, even though its widespread usage is limited due to high general toxicity and local toxicity to other organs. Taxol, a microtubule stabilizing agent, is an anticancer drug that induces cell apoptosis by inhibiting depolymerization of microtubules in between the metaphase and anaphase of the cell mitosis. Recently, its effectiveness and mechanism on various tumor has been reported. However, not much research has been done on the application of Taxol to oral squamous cell carcinoma. Cyclosporin A, which is an immunosuppressant, is being used on cancers and when co-administered with Taxol, effectiveness of Taxol is enhanced by inhibition of Taxol induced multidrug resistance. In this study, Cyclosporin A with different concentration of Taxol was co-administered to HN22, the oral squamous cell carcinomacell line. To observe the cell apoptosis and the mechanisms that take part in this process, mortality evaluation of tumor cell using wortmannin, c-DNA microarray, RT-PCR analysis, cytometry analysis and western blotting were used, and based upon the observation on the effect and mechanism of the agent, the following results were obtained: 1. The HN22 cell line viability was lowest when $100{\mu}M$ of Wortmannin and $5{\mu}g/ml$ of Taxol were co-administered, showing that Taxol participates in P13K-AKT1 pathway. 2. In c-DNA microarray, where $1{\mu}g/ml$ of cyclosporine A and 3mg/ml of Taxol were co-administered, no up regulation of AKT1, PTEN and BAD c-DNA that participate in cell apoptosis was observed. 3. When $1{\mu}g/ml$ of Cyclosporin A was applied alone to HN22 cell line, no difference was found in AKT1, PTEN and BAD mRNA expression. 4. Increased AKT1, mRNA expression was observed when $3{\mu}g/ml$ of Taxol was applied alone to HN22 cell line. 5. When $1{\mu}g/ml$ of Cyclosporin A and Taxol($3{\mu}g/ml\;and\;5{\mu}g/ml$) were co-administered to HN22 cell line, PTEN mRNA expression increased, whereas AKT1 and BAD mRNA decreased. 6. As a result of cytometry analysis, in the group of Cyclosporin A($1{\mu}g/ml$) and Taxol($3{\mu}g/ml$) co-administration, increased Annxin V was observed, which shows that apoptosis occurred by deformation of plasma membrane. However, no significant difference was observed with vary ing concentration. 7. In western blot analysis, no caspase 3 was observed in the group of Cyclosporin A($1{\mu}g/ml$) and Taxol($3{\mu}g/ml$) co-administration. From the results of this study, it can be concluded that synergistic effect can be observed in combination therapy of Taxol and Cyclosporin A on oral squamous cell carcinoma cell line, where decreased activity of the cell line was observed. This resulted in decreased AKT1 and BAD mRNA and increased PTEN mRNA expression and when wortmannin and Taxol were co-administered, the viability decreased which confirms that Taxol decreases the viability of tumor cell line. Hence, when Taxol and cyclosporine A are co-administered, it can be assumed that cell apoptosis occurs through AKt1 pathway.

Keywords

References

  1. Hromas RA, North JA, Burns CP: Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett 1987;36(2):197-201 https://doi.org/10.1016/0304-3835(87)90091-7
  2. Vikran B, Strong E, Shah J et al.: Failure at the primary site-following multimodality treatment for advanced head and neck cancer. Head Neck Surg 1984;6:720
  3. Lockshin RA and Williams CM: Programmed cell death. II. Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths. J Insect Physiol 1964;10:643-649 https://doi.org/10.1016/0022-1910(64)90034-4
  4. Choi EJ: Experimental & Molecular medicine Vol.33 Supplement, December 2001;83-93 https://doi.org/10.1038/emm.2001.15
  5. Fadeel B, Gleiss B, Hogstrand K et al: Phosphatidylserine exposure during apoptosis is a cell-type-specific event and does not correlate with plasma membrane phospholipid scramblase expression. Biochem Biophys Res Commun 1996;266(2):504-11
  6. Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256(1):42-9 https://doi.org/10.1006/excr.2000.4838
  7. Amos LA, Lowe J: Chem. Biol. 6, 65-69, 1999 https://doi.org/10.1016/S1074-5521(99)89002-4
  8. Crown J, O'Leary M: Lancet 355,1176-1178, 2000 https://doi.org/10.1016/S0140-6736(00)02074-2
  9. Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;9:92(10):4507-4511
  10. Wang TH, Popp DM, Wang HS, et al.: Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal Kinase(JNK)-dependent and independent pathways in ovarian cancer cell. J Biol Chem 1999;19(274)12:8208-8216
  11. Lu KH, Leu K, Liao HH, et al.: Induction of caspase -3-dependent apoptosis in human leukemia HL-60 cells by paclitaxel. Clin Chem Acta 2005;357(1):65-73 https://doi.org/10.1016/j.cccn.2005.02.003
  12. Park SJ, Wu CW, John D, et al. : Taxol Induces Caspase-10-dependent Apoptosis. J Bio Chem 2004;279(49) :51057-51067 https://doi.org/10.1074/jbc.M406543200
  13. Jordan MA, Wendell K, Gardiner S, et al.: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56(4):816-825
  14. Yvon AM, Wadsworth P, Jordan MA: Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999;10(4):947?959
  15. Laupacis A, Keown PA, Ulan RA: Cyclosporin A : a powerful immunosuppessant. Can med Assoc J 1986;126:1041
  16. Satoshi M, Shigeo K: Mechanisms of action of cyclosporine. Immunopharm 2000;47:119-125 https://doi.org/10.1016/S0162-3109(00)00192-2
  17. Braida M, Knop J: Effect of cyclosporin A on the T-effector and Tsuppressor cell response in contact sensitivity. Immun 1986;59:503-511
  18. Mongini C, Waldner C, Lopes EC, et al.: Induction of apoptosis in murine lymphoma cells by cyclosporin A. Int J Mol Med 2001; 7(4):431-437
  19. Healy E, Dempsey M, Lally C, et al.: Apoptosis and necrosis : mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 1998;54(6):1955-1966 https://doi.org/10.1046/j.1523-1755.1998.00202.x
  20. Justo P, Lorz C, Sanz A, et al.: Intracellular mechanisms cyclosporin A-induced tubular cell apoptosis. J Am Soc Nephrol 2003; 14(12):3072-3080 https://doi.org/10.1097/01.ASN.0000099383.57934.0E
  21. Zupanska A, Dziembowska M, Ellert MA, et al.: Cyclosporine A induces growth arrest or programmed cell death of human glioma cells. Neuro chem Int 2005;47(6):430-441 https://doi.org/10.1016/j.neuint.2005.05.010
  22. Lim HW, Kim KW: Anti-cancer effect of Cyclosporin A on oral squamous cell carcinoma cell line J Kor Oral Maxillofac Surg 2004;30(06):474-481
  23. Meerum-Terwogt JM, Malingre MM, Beijnen JH, et al.: Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Cli. Cancer Res 1999;5:3379-3384
  24. Kimura Y, Aoki J, Kohno M, et al.: P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 2002;49(4):322-8 https://doi.org/10.1007/s00280-001-0419-x
  25. Mirte MM, Dick JR, Jos H, et al.: Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncology 2001;19(4):1160-1166 https://doi.org/10.1200/JCO.2001.19.4.1160
  26. Koshkina NV, Golunski E, Roberts LE, et al.: Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 2004;17(1):7-14 https://doi.org/10.1089/089426804322994415
  27. Meerum Terwogt JM, Malingre MM, Beijnen JH, et al.: Clin Cancer Res. 1999;5(11):3379-84
  28. Lin HL, Lui WY, Liu TY, Chi CW: Reversal of Taxol resistance in hepatoma by cyclosporin A : involvement of the Pl-3 Kinase-Akt 1 pathway .British Jounal of Cancer 2003;88,973-980 https://doi.org/10.1038/sj.bjc.6600788
  29. Andjelkovic M, Jakubowicz T, Cron P, et al.: Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci USA 1996;93(12):5699-5704
  30. Datta SR, Dudek H, Tao X, et al.: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91(2):231-241 https://doi.org/10.1016/S0092-8674(00)80405-5
  31. Watanabe H, Saito H, Rychahou PG, et al.: Aging is associated with decreased pancreatic acinar cell regeneration and phosphatidylinosito 3-kinase/Akt activation. Gastroenterology. 2005;128(5):1391-1404 https://doi.org/10.1053/j.gastro.2005.03.016
  32. Jin Q. Cheng: Phosphoinositide 3-Kinase/Akt1 Pathway and Human Ovarian Cancer SEP 2002. Annual rept. 1 Sep 2001-31 ug 2002
  33. Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G, Bellacosa A, Capitani S, Martelli AM: The phosphoinositide 3-kinase/Akt1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 2003;1(3):234-46
  34. Polakis P: The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997;1332(3):F127-F147
  35. Brown JD, Moon RT. Wnt signaling: Why is everything so negative? Curr Opin Cell Biol 1998;10(2):182-187 https://doi.org/10.1016/S0955-0674(98)80140-3
  36. Bafico A, Liu G, Yaniv A, et al.: Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001;3(7):683-686 https://doi.org/10.1038/35083081
  37. Ohigashi T, Mizuno R, Nakashima J, et al.: Inhibition of Wnt Signaling Downregulates Akt Activity and Induces Chemosensitivity in PTEN-Mutated Prostate CancerCells Prostate 2005;62:61-68 https://doi.org/10.1002/pros.20117
  38. Simpson L, and Parsons R: PTEN : life as a tumor suppressor. Exp. Cell Res 2001;264:29-41 https://doi.org/10.1006/excr.2000.5130
  39. Maitra A, Hruban RH: A new mouse model of pancreatic cancer: PTEN gets its Akt together. Cancer Cell 2005;8(3):171-2 https://doi.org/10.1016/j.ccr.2005.08.007
  40. Arnaud B, Stephen MR, V. Wee Yong: PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem 1999;263:605-611 https://doi.org/10.1046/j.1432-1327.1999.00542.x
  41. Tamai K, Semenov M, Kato Y, et al: LDL-receptor-related proteins in Wnt signal transduction. Nature 2000;407(6803):530-535 https://doi.org/10.1038/35035117
  42. Li H, Zhu H, Xu C, et al: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94(4):491-501 https://doi.org/10.1016/S0092-8674(00)81590-1
  43. Amundson SA, Myers TG, Scudiero D, et al: An informatics approach identifying markers of chemosensitivity in human cancer cell lines Res 2000;60:6101-6110
  44. Reed JC: Prosmise and problem of Bcl-2 antisene therapy. J Natl / Cancer Inst 1997;89, 988-990 https://doi.org/10.1093/jnci/89.14.988
  45. Haldar S, Basu A, Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-233
  46. Stahl U, Wenk J, Wagener F, et al: Phosphoinositide 3-kinase(PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth. Pathologe 2004;25(1):31-7 https://doi.org/10.1007/s00292-003-0673-2
  47. Paez GP, Sellers WR: The PI3K/PTEN/Akt pathway: A critical mediator of oncogenicsignaling. In: Frank DA, ed. Signal Transduction in Cancer. Cancer Treat Res 2003;115:145-67
  48. Fruman, Meyers & Cantley, Katso et al., 2001; Vanhaesebroeck & Waterfield, 1999
  49. Vazquez F, Sellers WR: The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signalling. Biochem Biophys Acta 2000;1470:M21-M35
  50. Kandel ES, Hay N: The regulation and activities of the multi-functional serine/threonine kinase Akt/PKB. Exp Cell Res 1999;253:210-229 https://doi.org/10.1006/excr.1999.4690
  51. Stein RC, Waterfield MD: PI3-kinase inhibition : a target for drug development? Mol Med Today 2000;6:347-357 https://doi.org/10.1016/S1357-4310(00)01770-6
  52. Vanhaesebroeck B, Waterfield MD: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 253:239-254. doi:10.1006/excr. 4701, 1999
  53. Datta SR, Brunet A, Greenberg ME: Cellular survival : a play in three Akts. Genes Dev 1999;13(22):2905-27 https://doi.org/10.1101/gad.13.22.2905
  54. Plas DR, Thompson CB: Akt-dependent transformation : there is more to growth than just surviving. Oncogene 2005;24(50):7435-7442 https://doi.org/10.1038/sj.onc.1209097
  55. Zimmermann S, Moelling K: Phosphorylation and regulation of Raf by Akt(protein kinase B). Science 1999;286(5445):1741-1744 https://doi.org/10.1126/science.286.5445.1741
  56. Daniel T. Bergstralh, Jenny PY. Ting: Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination Cancer Treatment Reviews 2000;32:166-179 https://doi.org/10.1016/j.ctrv.2006.01.004
  57. Cheng JQ, Lindsley CW, Cheng GZ, et al: The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005;24(50): 7482-7492 https://doi.org/10.1038/sj.onc.1209088
  58. MacKeigan JP, Taxman DJ, Hunter D, et al: Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of Taxol and mitogen-activated protein kinase inhibition. Clin Cancer Res 2002;8(7):2091-2099
  59. Hu L, Hofmann J, Lu Y, et al: Inhibition of phosphatidylinositol 30-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Cancer Res 2002;62(4):1087-1092
  60. Shingu T, Yamada K, Hara N, et al: Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoin- ositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 2003;63(14):4044-4047
  61. Schultz RM, Merriman RL, Andis SL, et al: In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995;15:1135-1139
  62. Price BD, Youmell MB: The phosphatidylinositol 3-kinase inhibitor wortmannin sensitises murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res 1996;56:246-250
  63. Davol PA, Bizuneh A, Frackelton AR Jr.: Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo. Anti-cancer Res 1999;19:1705-1713
  64. Lemke LE, Paine-Murrieta GD, Taylor CW, Powis G: Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmocol 1999;44:491-497 https://doi.org/10.1007/s002800051123
  65. Amornphimoltham P, Sriuranpong V, Patel V, et al: Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004;15;10(12 Pt 1):4029-37
  66. Roymans D, Slegers H: Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 2001;268:487-498 https://doi.org/10.1046/j.1432-1327.2001.01936.x
  67. Li Y, Podsypanina K, Liu X, et al: Deficiency of pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2:2. doi: 10.1186/1471-2199-2-2, 2001
  68. Weng LP, Brown JL, Eng C: PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 2001;10:237-242 https://doi.org/10.1093/hmg/10.3.237
  69. Stefania Morrone: ANNEXIN V in 'Purdue Cytometry CD-ROM Series,volume 4'. Dept. Experimental Medicine & Pathology, University 'La Sapienza', Rome, Italy
  70. Vermes I, Haanen C, Steffens-Nakken H, et al : A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;17;184(1):39-51
  71. Rowinsky E: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48:353374
  72. Sharon L. Schendel, Zhihua Xie, Myrta Oblatt Montal, et. al.: Channel formation by antiapoptotic protein Bcl-2, Proc Natl Acad Sci USA 1997;13;94(10):5113-5118
  73. Ciechomska I, Pyrzynska B, Kazmierczak, et al: Signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cell. Oncogene 2003;23:22(48): 7616-27
  74. Bustamante J, Caldes Lopes E, Garcia M, et al: Disruption of mitochondrial membrane potential during apoptosis induced by Psc 833 and CsA in multidrug resistant lymphoid leukemia. Toxicol Appl Pharmacol 15 190(1):44-51 https://doi.org/10.1016/j.taap.2004.03.021
  75. Igarashi K, Hirotani H, Woo JT, et al.: Cyclosporin A and Fk506 induce osteoclast apoptosis in mouse bone marrow cell cultures. Bone 2004;35(1):47-56 https://doi.org/10.1016/j.bone.2004.02.009
  76. Kruijtzer CM, Schellens JH, Mezger J, et al.: Phase II and pharmacologic study of weakly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2002;20(23);4508-4516 https://doi.org/10.1200/JCO.2002.04.058
  77. Nomura T, Yamamoto H, Mimata H, et al.: Enhancement by cyclosporin A of taxol-indeced apoptosis of human urinary bladder cancer cells. Urol Res 2002;30(2):102-111 https://doi.org/10.1007/s00240-002-0239-4
  78. Kemper Em, van Zandberger Ae, Cleypool C, et al.: Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 2003;9(7):2849-2855
  79. Bardelimeijer HA, Ouwehand M, Meijnen JH, et al.: Efficacy of novel p-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drug 2004;22(3):219-229 https://doi.org/10.1023/B:DRUG.0000026248.45084.21
  80. Torres K, Horwitz SB: Mechanism of Taxol-induced cell death are concentration dependent. Cancer Res 1998;58:3620-3626